



OCT 15 2004

Practitioner's Docket No. MPI98-089CP2M

PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Glucksmann, Maria A., et al.		
Application No.:	09/964,008	Group No.:	1646
Filed:	September 26, 2001	Examiner:	O'Hara, Eileen B.
For:	15625 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A (1 page) and PTO/SB/08B (1 page)
3. ☒ Copies of Listed Information Items Accompanying This Statement (2 references)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: October 5, 2004

Sean Hunziker

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI98-089CP2M

**Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

October 5, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat  
Tracy M. Sioussat  
Reg. No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 374-7679  
Facsimile – (617) 551-8820



+
---

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Number</b>	09/964,008
<b>Filing Date</b>	September 26, 2001
<b>First Named Inventor</b>	Glucksmann, Maria A. et al
<b>Group Art Unit</b>	1646
<b>Examiner Name</b>	O'Hara, Eileen B.
<b>Attorney Docket Number</b>	MP198-089CP2M

**TECH CENTER 1600/2900**

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



+

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

*(use as many sheets as necessary)*

Sheet

1

of

---

1

**Complete if Known**

<b>Application Number</b>	09/964,008
<b>Filing Date</b>	September 26, 2001
<b>First Named Inventor</b>	Glucksmann, Maria A. et al.
<b>Group Art Unit</b>	1646
<b>Examiner Name</b>	O'Hara, Eileen B.
<b>Attorney Docket Number</b>	MPI98-089CP2M

[illegible]

Examiner  
Signature

Date  
Considered

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

+